Form

BioVie Inc. Announces Pricing of Public Offering

Retrieved on: 
Monday, March 4, 2024

The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering expenses.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • The offering is expected to close on March 6, 2024, subject to satisfaction of customary closing conditions.
  • The offering will be made only by means of a written prospectus.

First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering

Retrieved on: 
Monday, March 4, 2024

In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 525,625 shares of common stock.

Key Points: 
  • In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 525,625 shares of common stock.
  • Roth Capital Partners is acting as the exclusive placement agent for the offering.
  • The gross proceeds to the Company from this offering are expected to be approximately $4.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

VENTYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 4, 2024

Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.

Greystone Housing Impact Investors Files Form 10-K and Issues Investor Schedule K-1s 

Retrieved on: 
Monday, March 4, 2024

The Partnership’s unitholders may receive a hard copy of the Form 10-K free of charge upon request to the Partnership’s Investor Services department at (855) 428-2951.

Key Points: 
  • The Partnership’s unitholders may receive a hard copy of the Form 10-K free of charge upon request to the Partnership’s Investor Services department at (855) 428-2951.
  • The Partnership also announced that investors may now access their Tax Year 2023 Schedule K-1 forms using the Tax Package Support website at www.taxpackagesupport.com/greystone .
  • Investors with existing access to Tax Package Support can access their Partnership Schedule K-1 information using their existing accounts.
  • In addition to being available electronically, paper copies of investor Tax Year 2023 Schedule K-1 forms will be printed and mailed to investor addresses on file.

MAPLEBEAR INC. (NASDAQ: CART) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Maplebear Inc. d/b/a Instacart

Retrieved on: 
Monday, March 4, 2024

If you purchased or acquired Instacart securities, including pursuant to the IPO, and/or would like to discuss your legal rights and options please visit Maplebear Inc.

Key Points: 
  • If you purchased or acquired Instacart securities, including pursuant to the IPO, and/or would like to discuss your legal rights and options please visit Maplebear Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 25, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Retrieved on: 
Saturday, March 2, 2024

The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.
  • The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
  • In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to 2,300,000 shares of common stock.
  • The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

MAISON SOLUTIONS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Maison Solutions Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

Investors have until March 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • On May 22, 2023, Maison Solutions filed a registration statement on Form S-1, which after six amendments (and three post-effective amendments) was declared effective on September 29, 2023.
  • On October 5, 2023, Maison Solutions filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the “Prospectus” and, together with the Registration Statement, the “Offering Documents”).

BioVie Inc. Announces Proposed Public Offering of Common Stoc

Retrieved on: 
Friday, March 1, 2024

All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

Key Points: 
  • All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.
  • ThinkEquity LLC (“ThinkEquity”) is acting as sole placement agent for the offering.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, March 1, 2024

The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.

Key Points: 
  • The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million.
  • All of the shares in the offering were sold by Absci.
  • The shares of common stock were offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No.

REE Announces Pricing of Public Offering of Ordinary Shares

Retrieved on: 
Friday, March 1, 2024

TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), today announced the pricing of an underwritten public offering of 2,000,000 Class A ordinary shares (the “ordinary shares”).

Key Points: 
  • TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), today announced the pricing of an underwritten public offering of 2,000,000 Class A ordinary shares (the “ordinary shares”).
  • Each ordinary share is being sold at a public offering price of $6.50 per share.
  • The Company has granted the underwriter a 20-day option to purchase up to an additional 300,000 ordinary shares sold in the offering to cover over-allotments, if any.
  • REE intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including continued product development and commercialization.